Trial Investigating Pembrolizumab for Hormone-Sensitive Prostate Cancer Discontinued
Merck has decided to end the phase 3 KEYNOTE-991 trial due to futility.
Merck has decided to end the phase 3 KEYNOTE-991 trial due to futility.
Among African-American cancer survivors, experiencing discrimination is associated with frailty, a study suggests.
New findings could have implications for the use of salvage therapies.
Investigators analyzed data from 3 randomized controlled trials and data from their own prospective institutional database.
New research suggests that men with localized prostate cancer have low prostate cancer-specific mortality at 15 years, regardless of the treatment they receive.
Pluvicto is currently in shortage due to challenges in meeting demand and no therapeutic equivalents being available.
From 2014 to 2021, the rates of active surveillance for low-risk prostate cancer increased, but there was considerable variation in its use.
Of the 9 novel variants, 7 were only found or were more common in men of African ancestry.
Greater depth of PSA decline is associated with improved outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with enzalutamide.
A meta-analysis suggests that abiraterone-based triplet therapy may be best for high-volume mCSPC, and API-based doublet regimens may be best for low-volume mCSPC.